Lipoprotein-associated phospholipase A2 and diabetic peripheral neuropathy

This study explores the potential role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in diabetic peripheral neuropathy (DPN) among patients with type 2 diabetes mellitus (T2D). Lp-PLA2, an enzyme involved in inflammatory and atherosclerotic processes, has previously been associated with cardiovascular disease and diabetic microvascular complications, although its role in DPN remains unclear. The authors discuss findings from a cross-sectional study including 880 hospitalized patients with T2D, showing that higher Lp-PLA2 levels were significantly associated with an increased prevalence of DPN. Patients in the highest quartile of Lp-PLA2 exhibited a greater likelihood of neuropathy compared with those in the lowest quartile. The article also highlights possible underlying mechanisms, including chronic inflammation, oxidative stress, endothelial dysfunction, and neuronal damage. Overall, the findings suggest that Lp-PLA2 may serve as a promising biomarker for early diagnosis and risk stratification of DPN, potentially contributing to the development of novel diagnostic and therapeutic strategies for diabetic complications.